We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based Verona Pharma have announced the dry powdered inhaler (DPI) formulation of ensifentrine for chronic obstructive pulmonary disorder (COPD) has achieved all the endpoints in a Phase II trial.
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).